<DOC>
	<DOCNO>NCT00537420</DOCNO>
	<brief_summary>The purpose study determine effect nasal PYY3-36 weight loss post 24 week treatment .</brief_summary>
	<brief_title>A Study Nasal PYY3-36 Placebo Weight Loss Obese Subjects</brief_title>
	<detailed_description>This multi-center , Phase 2 double-blind , randomize , placebo-controlled trial healthy obese patient . The primary objective study evaluate effect increase nasal PYY3-36 dosing weight loss post 24 week treatment . Secondary Objectives : - To evaluate safety three nasal PYY3 36 dose group compare nasal placebo - To compare weight loss post 12 24 week treatment three nasal PYY3 36 dose group versus nasal placebo group - To compare proportion patient lose least 5 % 10 % baseline body weight post 12 24 week therapy three nasal PYY3 36 dose group versus nasal placebo group - To compare weight loss proportion patient lose least 5 % baseline body weight post 12 24 week treatment sibutramine versus capsule placebo - To compare weight loss proportion patient lose least 5 % baseline body weight post 12 24 week treatment nasal placebo versus capsule placebo - To compare weight loss proportion patient lose least 5 % baseline body weight post 12 24 week treatment sibutramine versus nasal PYY3 36 dose group - To evaluate effect 12 24 week treatment nasal PYY3 36 sibutramine fast lipid profile , plasma glucose , insulin , blood pressure pulse , waist circumference BMI - To evaluate effect 24 week treatment nasal PYY3 36 sibutramine HbA1c level</detailed_description>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Sibutramine</mesh_term>
	<criteria>Male Female patient 18 65 year , inclusive ; BMI 3043 kg/m2 , inclusive ; In good health , determine medical history physical examination , well normal 12lead ECG vital sign ; Nonsmoker use tobacco nicotine product least 3 month ; Females nonpregnant , nonlactating , either postmenopausal least 1 year , surgically sterile ( include tubal ligation , hysterectomy ) least 3 month , 30 day follow Study Completion willing use approve method contraception ; Has normal nasal mucosa . Previous surgical treatment obesity ; Serious Medical Condition Serious Psychiatric illness Organic cause obesity ( e.g . untreated hypothyroidism ) Type 1 Type 2 Diabetes ; Presence uncontrolled hypertension On prohibit concomitant medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>weight loss</keyword>
	<keyword>diet</keyword>
</DOC>